New Strategies in Aggressive B-Cell Lymphomas: Advances, Application, and a Glimpse of the Future

Register now for this interactive satellite symposium held in Conjunction with the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois to hear about the recent and evolving treatment strategies in the management of patients with aggressive B-cell lymphomas. After the symposium, view the on-demand webcast and download the associated slideset for use in your clinic.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

 

Agenda

Welcome and Introduction

Prognostic and Predictive Biomarkers in Aggressive B-cell Lymphomas; Role in Treatment Selection

  • Mantle-Cell Lymphoma (MCL)
  • Diffuse Large B-Cell Lymphoma (DLBCL)

Patient Selection and Treatment Sequencing; Integrating

Precision Medicine Approaches into the Current Treatment Algorithm

New and Emerging Agents and Clinical Application of New Advances in MCL and DLBCL

Case Presentations and Panel Discussions Addressing Treatment Challenges and Future Directions in MCL and DLBCL

Key Takeaways and Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Faculty
Jeremy S. Abramson, MD, MMSc

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Faculty
Grzegorz Nowakowski, MD

Professor of Medicine and Oncology
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Program Overview
This program will provide expert faculty perspectives on the optimal integration of new classes of agents and treatment regimens into the management of MCL and DLBCL, and contextualize the role of prognostic and predictive biomarkers for risk stratification and personalization of patient care using clinical case studies to illustrate how to utilize precision medicine approaches for the selection and sequencing of therapy to achieve optimal efficacy and safety.

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with MCL and DLBCL.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with B‑cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order and interpret molecular profiling for appropriate patients with MCL and DLBCL to guide therapy selection
  • Select treatment regimens for patients with MCL and DLBCL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with aggressive B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of MCL and DLBCL

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.